Sarepta's Vyondys 53 Receives FDA Approval For DMD, Stock Up
Zacks Investment Research | Dec 12, 2019 08:13PM ET
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that the FDA granted accelerated approval to Vyondys 53 (golodirsen) for the treatment of patients with Duchenne muscular dystrophy (“DMD”) who are exon 53 amenable. Vyondys 53 is Sarepta’s second approved exon-skipping RNA therapy for DMD. The company will launch the drug immediately.
The company has to conduct a post-marketing confirmatory study to convert the accelerated approval to a continued approval for Vyondys 53. We note that Sarepta is already conducting a similar study – ESSENCE. The study is currently enrolling patients and is expected to conclude by 2024.
Please note that the new drug application (“NDA”) seeking approval for Vyondys 53 had received a complete response letter (“CRL”) from the FDA in industry ’s increase of 6.3%.
The approval to Vyondys 53 is likely to boost total revenues for Sarepta. The company’s already approved DMD drug, Exondys 51, treats patients who are exon 51 amenable. Exondys 51 has generated sales of $280.7 million in the first nine months of 2019, up almost 30% year over year. The company stated that Vyondys 53 will increase eligible DMD patient population by 8% in the United States. Both the drugs combined will offer treatment options for approximately 20% of U.S. DMD patients.
The company is developing another exon-skipping RNA therapy, casimersen, for DMD patients who are exon 45 amenable. It stated in its third-quarter earnings release that it will submit a NDA for the candidate following clarity on golodirsen NDA. Thus, we expect the company to file the same with the FDA soon.
Sarepta is also developing next-generation PPMO platform candidate, SRP-5051, in DMD patients amenable to exon 51 skipping and gene therapies targeting DMD and other muscular dystrophies as well as central nervous system disorders.
Meanwhile, there are several other companies developing gene therapies for treating DMD including Solid Biosciences (NASDAQ:SLDB) , Audentes Therapeutics (NASDAQ:BOLD) and Pfizer (NYSE:PFE) . Successful development of gene therapies for DMD will increase competition in the field.
Sarepta Therapeutics, Inc. Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.